

VARIABILITY OF *PDYN* AND *OPRK1* GENES IN FOUR ARGENTINIAN POPULATIONS AND ITS GENETIC ASSOCIATION WITH CLINICAL VARIABLES RELATED TO ACUTE POSTSURGICAL PAIN



VARIABILIDAD DE LOS GENES *PDYN* Y *OPRK1* EN CUATRO POBLACIONES ARGENTINAS Y SU ASOCIACIÓN CON VARIABLES CLÍNICAS RELACIONADAS AL DOLOR AGUDO POST-QUIRÚRGICO

Di Santo Meztler G.P.^{1,2}, Schiaffi J.³, Rigalli A.⁴, Esteban Torné M.E.⁵, Martina P.F.⁶, Catanesi C.I.^{2,7}

¹ CIProVe-Centro Asociado CICPBA-UNLP, Depto. de Cs. Biológicas, Facultad de Cs. Exactas, UNLP, La Plata, Argentina.

² Laboratorio de Diversidad Genética, Instituto Multidisciplinario de Biología Celular- IMBICE (CONICET CCT-La Plata; CICPBA; UNLP), La Plata, Argentina.

³ Servicio de Ginecología del Hospital General de Agudos Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina.

⁴ Centro Universitario de estudios Medioambientales, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina.

⁵ Section of Zoology and Biological Anthropology, Department of Evolutionary Biology, Ecology, and Environmental Sciences, and Biodiversity Research Institute, University of Barcelona, Barcelona.

⁶ Facultad de Cs. Exactas, Químicas y Naturales, Universidad Nacional de Misiones, Posadas, Misiones, Argentina.

⁷ Facultad de Cs. Naturales y Museo, Universidad Nacional de La Plata (UNLP), La Plata, Buenos Aires.

Corresponding author:
Catanesi, Cecilia Inés
ccatanesi@imbice.gov.ar

 ORCID 0000-0002-5970-5027

Cite this article as:

Di Santo Meztler G.P., Schiaffi J., Rigalli A., Esteban Torné M.E., Martina P.F., Catanesi C.I. 2022. VARIABILITY OF *PDYN* AND *OPRK1* GENES IN FOUR ARGENTINIAN POPULATIONS AND ITS GENETIC ASSOCIATION WITH CLINICAL VARIABLES RELATED TO ACUTE POSTSURGICAL PAIN. BAG. Journal of Basic and Applied Genetics XXXIII (2): 7-18.

Received: 08/20/2021

Revised version received: 02/04/2022

Accepted: 05/03/2022

General Editor: Elsa Camadro

DOI: 10.35407/bag.2022.33.02.01

ISSN online version: 1852-6233

ABSTRACT

Several population studies showed an association between variation in pain sensitivity and genetic polymorphisms located in Prodynorphin (*PDYN*) and Kappa Opioid Receptor (*OPRK1*) human genes. We analysed polymorphisms of these two genes to characterise their variation in Argentinian populations, as well as to evaluate their association with acute pain sensitivity. We studied 11 genetic markers in individuals from four locations in Argentina (Ciudad Autónoma de Buenos Aires, La Plata, Resistencia, and Misiones Nueva Pompeya), calculated the population parameters, and evaluated the possible association among pain sensitivity, clinical, and genetic variables through a Generalised Estimating Equation model. High linkage disequilibrium was observed in the four populations for both genes, and significant differences were found among frequencies of Argentinian populations and those from other continents reported in the 1000 Genomes Project. Four *PDYN* gene polymorphisms from 3' untranslated region and exon 4 showed association with acute pain sensitivity. One genotype of each of these polymorphisms was associated with a higher pain sensitivity, probably related with the activation of the N-methyl-D-aspartate (NMDA) receptors. We found a strong association with acute pain for the following clinical variables: 1) time after surgery, 2) intravenous klosidol supplied every 8 h, and 3) type of incision. Our results highlight the importance of a regional study of genetic variants which influence pain sensitivity and analgesic response.

Key words: human populations, pain sensitivity, acute pain, genetic polymorphisms, genetic structure

RESUMEN

La asociación entre la sensibilidad al dolor y los polimorfismos que presentan los genes humanos de prodinorfina (*PDYN*) y receptor opioide kappa (*OPRK1*) se ha evidenciado en distintos estudios poblacionales. Con el objetivo de caracterizar la variación de estos genes y evaluar su asociación con dolor agudo en la población argentina, analizamos 11 polimorfismos en individuos provenientes de cuatro localidades argentinas (Ciudad Autónoma de Buenos Aires, La Plata, Resistencia, y Misiones Nueva Pompeya). Calculamos los parámetros poblacionales y evaluamos la posible asociación entre sensibilidad al dolor, variables clínicas y variables genéticas a través de un modelo de ecuación generalizada de estimación. Se observó alto desequilibrio de ligamiento para ambos genes en las cuatro poblaciones analizadas, y se encontraron diferencias significativas entre las frecuencias de poblaciones argentinas y las reportadas en el Proyecto 1000 Genomes para poblaciones de otros continentes. Cuatro polimorfismos de la región 3'UTR y el exón 4 de *PDYN* mostraron asociación con la sensibilidad al dolor agudo. En cada uno de estos polimorfismos, un genotipo resultó asociado con alta sensibilidad al dolor, probablemente en relación con la activación de receptores N-metil-D-aspartato (NMDA). Encontramos una fuerte asociación con dolor agudo para las siguientes variables clínicas: 1) tiempo post-cirugía, 2) administración intravenosa de klosidol cada 8 h, y 3) tipo de incisión. Nuestros resultados resaltan la importancia de realizar estudios regionales de variables genéticas que influyen en la sensibilidad al dolor y la respuesta analgésica.

Palabras clave: poblaciones humanas, sensibilidad al dolor, dolor agudo, polimorfismos genéticos, estructura genética

INTRODUCTION

The available information on the human genome gives a starting point for searching in different populations and among individuals for genome variability related to pain sensitivity and to the effectiveness of different drugs in pain relief (Owusu Obeng *et al.*, 2017; Crews *et al.* 2021). The human prodynorphin gene (*PDYN*), located on chromosome 20, encodes α -neoendorphin, β -neoendorphin, dynorphin A and dynorphin B. These molecules selectively activate kappa opioid receptors (KOR), encoded by *OPRK1* gene, which is located on chromosome 8 (Schwarzer, 2009; Hashemi *et al.*, 2018). Genetic association studies gave evidence of a link among certain DNA sequence variants of both genes and various pathologies, including cognitive disorders and drug abuse, as well as variations in pain sensitivity (Clarke *et al.*, 2012; Hashemi *et al.*, 2018; Nosova *et al.*, 2021).

It has been reported that an efficient management of postoperative acute pain is essential not only for improving the wellness of the patient, but also for reducing the risk of chronicity of pain, morbidity and mortality (Carr and Goudas, 1999). Genetic polymorphisms can explain some of the variation in response to analgesics, while other important variables also involved are the sex of the patient, the intensity and kind of pain, the environmental influences, and several psychological aspects including among others, anxiety and somatization (Stamer and Stüber, 2007; Schreiber *et al.*, 2014).

The challenge is to decipher the biological basis of such a complex phenotype, considering pain perception and response to analgesic drugs, both showing clear differences among populations of distinct origins. In Argentina, the current population is the result of several generations of intermixing among various groups at different times, including indigenous (Amerindian) communities, Spanish conquerors (early 1500s), Africans (arriving as slaves since the late 1500s until the end of slavery), and a large European immigrant population (arriving between 1870 and 1950) (Avena *et al.*, 2006). In this work we analyse four different populations from Argentina, namely from Ciudad Autónoma de Buenos Aires (CABA), La Plata, Resistencia, and Misión Nueva Pompeya (MNP).

Historical events

Ciudad Autónoma de Buenos Aires (CABA) is the capital city of Argentina and it has by far the largest population in the country. During the second half of the 20th century, a significant demographic increment occurred in Argentina, mainly due to migratory flows (Gallo and Cortés Conde, 1967). From 1940 onwards, the industrial development encouraged people to move

to CABA from other provinces of Argentina and from bordering countries bringing their indigenous genetic component (Torrado, 1992). While the European migratory contribution declined after 1930, immigrants from bordering countries are currently increasing the foreigner's contribution to the city (Avena *et al.*, 2001).

La Plata is the capital city of Buenos Aires province. Located 56 km southeast from CABA, it is the fourth most populous city in the country. As in CABA, an important European contribution in the past century is currently complemented by the arrival of populations from bordering countries looking for employment (Cerrutti, 2009).

In the case of Chaco province, it was originally inhabited by native people until 1528, when the first Europeans arrived. In 1872, a group of people from the province of Corrientes and Italian immigrants settled in this region. The city of Resistencia was then founded, and in 1884 it was assigned as the capital of the province of Chaco (De Pompert de Valenzuela, 2008; Tissera, 2008). At the end of the 19th century, European immigration to Resistencia was in order to promote urbanization and agricultural development (Maeder, 2012).

In 1900, the Franciscan missionaries founded the location of Misión Nueva Pompeya (MNP) in the western region of this province known as the *Impenetrable Chaqueño*. Currently, an important number of Native American people of the Wichí community still live in this inner region (Franceschi, 2010).

A previous report on the urban people living in MNP estimated a native contribution of 25% uniparental genetic markers (Sevini *et al.*, 2013). In fact, within the province of Chaco, Native American people from different communities live nearby several cities, and they still retain their traditional semi nomadic habits. The numerical importance of these native communities puts Chaco at present among the provinces with the highest number of living Native American people in Argentina (Instituto Nacional de Asuntos Indígenas, 2005).

Previous studies have shown genetic differences between these four populations using non coding X chromosome markers (SNPs, INDELs and STRs) (Di Santo Meztler, 2018; Di Santo Meztler *et al.*, 2019). Also, differences between a native Wichí community of Chaco and the population of Resistencia were found in the *OPRK1* gene (Raggio *et al.*, 2018).

In this work, our aim was to analyse whether interpopulation differences observed for non-coding genetic markers are also noticeable in coding regions, particularly for two genes of the opioid system and, therefore, to understand whether those differences have influence on the perception of pain. In particular, we focused on the genetic variability of *PDYN* and *OPRK1* in four Argentinian populations. Genetic association with clinical variants influencing pain sensitivity was

analysed for one of the populations, particularly after a surgical intervention.




Figure 1. Location of the Argentinian populations analysed in this work. 1 = Ciudad Autónoma de Buenos Aires, 2 = La Plata, 3 = Resistencia, 4 = Misión Nueva Pompeya.

MATERIALS AND METHODS

Populations

Between 2009–2012 we collected a total of 286 samples from adult, unrelated persons from four different locations in Argentina: the capital city of Argentina, CABA (n=106), the capital city of Buenos Aires province, La Plata (n=33), the capital city of Chaco province, Resistencia (n=96), and a small city of Chaco province, MNP (n=54). Figure 1 shows a map indicating these locations. Samples from La Plata, Resistencia and MNP consisted of both male and female donors, and were collected during three field trips. Samples from CABA were only female donors, which were collected at Gynecology Service's Breast Pathology Section of the Hospital General de Agudos Bernardino Rivadavia. The intensity of perceived pain and the requirement of analgesia after gynecological surgery were recorded for 50 out of 106 females from CABA. After discarding individuals with one or more missing data, the genetic association study was performed for a sample size of 35 females.

DNA was isolated from buccal and blood cells following protocols described in Gemmel and Akiyama

(1996). *OPRK1* data for the population of Resistencia were previously reported in Raggio *et al.* (2018) and were included in this work for comparison. All biological samples were genotyped by author G. P. Di Santo Meztler at the Instituto Multidisciplinario de Biología Celular (IMBICE).

This study was part of a project previously approved by the Ethics Committee of the IMBICE, and all donors gave written consent for participation in the study.

Genetic determinations

Eight polymorphisms (rs35286281, rs1997794, rs2235751, rs6045819, rs10485703, rs910080, rs910079, and rs2235749) were genotyped for *PDYN* gene, and three polymorphisms (rs35566036, rs3808627 and rs6985606) for *OPRK1* gene (Table 1). Genotyping was performed by PCR and separation of amplified fragments in 1.8% agarose gels, except for rs10485703, rs910080, rs910079 and rs2235749, which were amplified together in a fragment by PCR and then sequenced. For rs35286281 VNTR polymorphism, alleles were designated as 1(271pb), 2(339pb), 3(407pb) or 4(475pb) based on the number of repeated elements that were identified. Such elements contain a transcription factor binding site that is associated with transcriptional efficiency of the human *PDYN* gene, and higher gene expression is associated with repeated alleles 3 or 4 (Zimprich *et al.*, 2000). Therefore, the alleles 1 and 2 were categorised as low (L), and the alleles 3 and 4 as high (H) gene expression.

Primers for *PDYN* VNTR were obtained from Nikoshkov *et al.* (2008), primers for the SNPs located in the 3' untranslated region (3'-UTR) of the gene were obtained from Yuferov *et al.* (2009), and primers for rs1997794, rs2235751 and rs6045819 were designed for this work (Supplementary Table 1).

Primers for *OPRK1* INDEL (rs35566036) were obtained from Edenberg *et al.* (2008) and allele specific primers for *OPRK1* SNPs were designed in our lab and reported in Raggio *et al.* (2018).

Statistical analysis

Population study

For the genetic polymorphisms, allele frequencies were calculated using R v. 3.6.3 program (R Core Team, 2021). Heterozygosity, Hardy-Weinberg equilibrium (HWE) and genetic distance (as pairwise *Fst* values) were calculated through the program ARLEQUIN v.3.5 (Excoffier and Lischer, 2010), and linkage disequilibrium (LD) was calculated using the webtool SNPStats (Solé *et al.*, 2006) for obtaining both *D'* and *r* values. In the case of repetitive polymorphism rs35286281, the alleles were pooled into short (271 and 339) and long (407 and

Table 1. Change and location of the analysed polymorphisms

Gene/Marker	Change	Location
PDYN		
rs35286281	VNTR	promoter (1978756-1994285)
rs1997794	C-T	5'-UTR (1994212) a
rs2235751	A-G	intron 2 (1989288) a
rs6045819	A-G	exon 4 (1980488) a
rs10485703	C-T	3'-UTR (1979667) a
rs910080	C-T	3'-UTR (1979580) a
rs910079	C-T	3'-UTR (1979552) a
rs2235749	C-T	3'-UTR (1979293) a
OPRK1		
rs35566036	in-del	promoter (54328138: 54328137)
rs3808627	A-G	promoter (53252242) a
rs6985606	A-G	intron 2 (53248556) a

a: Location according to NCBI (dsSNP - GRCh38)

475) given that extreme alleles (271 and 475) are very infrequent, so that pooling them would produce no bias. The adaptation of the tables for R program and ARLEQUIN was made using GA-TA program (<https://github.com/santimda/GA-TA>) (Gamboa Lerena *et al.*, 2020). For population comparisons, data of four populations from 1000 Genomes database were included: Japanese in Tokyo (JPT); Mexican ancestry from Los Angeles (MXL), California, USA; residents of Utah with North and Western European ancestry (CEU) and Yoruba in Ibadan, Nigeria (YRI). Allele frequencies of these reference populations are detailed in Supplementary Table 2.

Association study

For the association study we considered only females from the sample of CABA without missing data (n=35). We analysed the variation of pain informed by the physicians in a follow-up of 1, 2, 12 and 24 h after surgery; although the observations were informed by different surgeons, all pain reports were registered under supervision of author J. Schiaffi. For this analysis two models were evaluated: in one case the dependent variable was the pain scale reported by the physician, who considered wound palpation, analgesia requirement, possibility of walking, and pain escalation according to medical impression (model M); while in the other model the scale was reported by the patient according to self-perception (model P).

The independent variables used in both models were the above mentioned polymorphisms of *PDYN* and *OPRK1* genes (Table 1), and the clinical variables time after surgery, age of the patient, dose of intravenous Klosidol (Bagó Laboratory, Argentina) -which consists of a combination of dextropropoxyphene hydrochloride

Table 2. Clinical variables included in the analysis

Clinical variable	Abbreviation	Levels
Time after surgery	Time	1 h after
		2 h after
		12 h after
		24 h after
Age of the patient	Age	-
Intravenous Klosidol	Ke8	No
		Yes
Associated pathologies	AP	No
		Yes
Type of incision	I	Median Infraumbilical laparotomy (I1)
		Pfannenstiel laparotomy incisions or breast surgery (I2)
		Radian (I3)
		Arcuate (I4)
		Stewart mastectomy (Orr type) incision (I5)

and dipyrone, supplied every 8 h according to pain intensity-, associated pathologies, and type of incision (Table 2). The type of incision depended on the type of surgery, which was either gynecological surgery (Median Infraumbilical laparotomy, and Pfannenstiel laparotomy incisions) or breast surgery (Radian, Arcuate, and Stewart mastectomy -Orr type- incisions). The analyses were made using R v.3.6.3, and GEE (Generalised Estimating Equation) model fitting was performed with the *geepack* library (Halekoh *et al.*, 2006).

RESULTS

Population genetic analysis

Allele frequencies for the *PDYN* and *OPRK1* polymorphisms are detailed in Table 3, and genotype frequencies in Supplementary Table 3. In the case of MNP, for rs35286281 the frequency of genotype 339/407 was higher than in the other populations, and for rs6045819 genotype G/G was absent. In none of the populations the genotype C/C was observed for rs10485703. In the case of Resistencia, for rs35566036 the frequency of genotype del/del was higher and that of the genotype in/del was lower than in the other populations.

For MNP, all the polymorphisms fitted HWE (p -value>0.05), but for the other three populations some of the markers did not fit HWE (Table 3). As we expected, linkage disequilibrium for *PDYN* gene was considerably high in all the populations. CABA and Resistencia showed higher LD than La Plata and MNP. For *OPRK1* the LD was lower in Resistencia and La Plata, while in CABA and MNP there were significant values of LD for all the markers (Supplementary Table 4).

Table 3. Allele frequencies and Hardy-Weinberg Equilibrium *p*-values for the polymorphisms analysed. For biallelic polymorphisms, one of the allele frequencies is showed.

Gene	Locus	Allele	CABA		La Plata		Resistencia ^a		MNP	
			freq.	p-value	freq.	p-value	freq.	p-value	freq.	p-value
PDYN	rs35286281	271	0.01		0.03		0.01		--	
		339	0.36	0.017	0.27	0.785	0.34	1.000	0.44	0.408
		407	0.62		0.68		0.64		0.55	
		475	0.01		0.02		0.02		0.01	
	rs1997794	C	0.42	0.016	0.31	0.296	0.39	0.829	0.42	0.577
	rs2235751	A	0.68	0.000	0.66	0.689	0.72	0.456	0.66	1.000
	rs6045819	A	0.87	0.368	0.88	0.048	0.91	1.000	0.94	1.000
	rs10485703	C	0.15	1.000	0.05	1.000	0.09	1.000	0.07	1.000
	rs910080	C	0.38	0.261	0.27	0.393	0.29	0.149	0.42	0.390
	rs910079	C	0.37	0.251	0.27	1.000	0.29	0.093	0.40	0.564
OPRK1	rs2235749	C	0.62	0.259	0.74	0.638	0.69	0.055	0.60	0.545
	rs35566036	300	0.75	1.000	0.66	1.000	0.88	0.000	0.67	0.375
	rs3808627	A	0.30	0.013	0.26	0.016	0.20	0.000	0.31	0.508
	rs6985606	A	0.33	0.653	0.35	0.005	0.30	0.000	0.24	0.707

CABA= Ciudad Autónoma de Buenos Aires; MNP= Misión Nueva Pompeya
^a: *OPRK1* data from Raggio *et al.* (2018)

The genetic distances were calculated for all the populations, and *F_{st}* with *p*-values lower than 0.05 were considered as significant (Tables 4 and 5). All four Argentinian populations showed significant differences with Africans from the Yoruba tribe in both genes, and also with Asians from Japan in *PDYN*, but differences in *OPRK1* resulted only significant for Resistencia. On the contrary, *OPRK1* resulted in significant values in the comparison with Europeans, while no differences were found when comparing with Mexicans for these two genes. Within Argentina, no differences were found for the SNPs comparisons (Table 4), whereas rs35566036 INDEL of *OPRK1* showed a differentiation among Resistencia and the other three Argentine populations, and rs5286281 VNTR of *PDYN* resulted significant only for CABA-MNP (Table 5).

Association Study

GEE analysis

Two GEE models were used to evaluate the association of the reported pain scale with the following variables: age of the patient (Age), dose of intravenous dextropropoxyphene hydrochloride + dipyrone every 8 hrs (Ke8), associated pathologies (AP), type of incision

(I), time after surgery (Time) and the genotypes for each polymorphism. Model M was based on the pain scale reported by the physician (MScale) and Model P on the pain reported by the patient (PScale). Thus,

- Model M-->MScale(Time, Age, AP, Ke8, I, genetic polymorphisms)
- Model P-->PScale(Time, Age, AP, Ke8, I, genetic polymorphisms)

For this study we used 7 out of 11 genetic polymorphisms that fitted HWE (*p*-value>0.05). We only focused on these polymorphisms for the association study in order to avoid statistical artifacts of markers out of HWE, probably given by the sample size, so that we can reach an accurate association between genetic markers and pain. The ANOVA *p*-values obtained with the GEE models are shown in Table 6, where *p*-values<0.01 were considered as significant values.

After analysing the results of the previous GEE models, three clinical variables presented a strong association with pain (*p*-value<0.01) for the model M: Time, Ke8, and I, while for Model P only Time and I were significant. Regarding genetic polymorphisms, 5 out of 7 were significant for model M while 2 out of 7 resulted significant for Model P (Table 6A). Once the variables influencing pain sensation were identified, the analysis

Table 4. Pairwise genetic distances (Fst values) for SNP markers among the analysed populations and data from the 1000 Genomes Project. Above the diagonal: Fst values for OPRK1 markers; and below the diagonal: Fst values for PDYN markers. Significant Fst values (p-value <0.05) are highlighted in bold.

Pairs of populations	CABA	La Plata	Resistencia	MNP	JPT ^a	MXL ^a	CEU ^a	YRI ^a
CABA		-0.007	0.011	0.004	-0.002	-0.006	0.033	0.337
La Plata	-0.010		-0.003	0.007	0.006	-0.009	0.014	0.461
Resistencia	-0.001	-0.008		0.015	0.031	0.010	0.038	0.256
MNP	-0.006	-0.012	-0.005		0.004	0.010	0.075	0.379
JPT ^a	0.280	0.317	0.326	0.305		0.002	0.049	0.345
MXL ^a	0.001	-0.007	-0.006	-0.004	0.351		0.018	0.387
CEU ^a	0.005	-0.002	-0.003	0.001	0.360	-0.006		0.401
YRI ^a	0.280	0.289	0.327	0.302	0.148	0.341	0.356	

References: CABA = Ciudad Autónoma de Buenos Aires; MNP = Misión Nueva Pompeya; JPT = Japanese in Tokyo; MXL = Mexican ancestry from Los Angeles, California USA; CEU = Residents of Utah with North and Western European ancestry; YRI = Yoruba in Ibadan, Nigeria.
a: data from the 1000 Genomes Project

Table 5. Genetic differentiation (pairwise Fst values) for OPRK1 INDEL (rs35566036) and PDYN VNTR (rs35286281), among the analysed populations, and in comparison to data from other reports. Significant values (p<0.05) are in bold.

Populations	OPRK1 rs35566036				
	CABA	La Plata	Resistencia	MNP	Eur. Americans ^a
CABA		-0.001	0.225	0.024	0.032
La Plata	-0.002		0.346	-0.017	0.099
Resistencia	0.008	-0.011		0.394	0.119
MNP	0.039	0.03	0.007		0.141
Germans ^b	0.009	-0.015	-0.008	0.013	

PDYN rs35286281

References: ^a: OPRK1 INDEL results were compared to non-Hispanic European Americans from Edenberg et al. (2008)

^b: PDYN VNTR results were compared to Germans from Zimprich et al. (2000)

was focused within each level of the clinical variables and polymorphisms, taking into account one level per variable as a reference.

The reference level were 1 h after surgery (Time1), no analgesia rescue (Ke8(No)), Median Infraumbilical Laparotomy (I1), and no associated pathology (AP(No)), which were set at a coefficient value of zero (Table 6B). Thus, negative coefficients indicate pain decrease in comparison to the reference case. Postsurgical acute pain intensity was found to decrease as time increased in hours in both models, showing negative coefficients: Time 2(-1), Time 12(-1.556), Time 24(-2.259) for model M. The action of analgesia rescue (Ke8Yes) resulted in the same direction, showing a high negative coefficient.

Additionally, an ANOVA analysis was performed considering Time separately for one surgical incision

at a time. ANOVA results for the first and second hours after the intervention were non-significant, but differences emerged for the reports at 12 and 24 h after incision (data not shown). The Pfannenstiel, Radian, Arcuate, and Orr surgery incisions showed a higher decrease of pain scale, with respect to the reference type of incision (Median Infraumbilical Laparotomy), being Pfannenstiel, Radian and Orr, the types of incision that presented the most important decrease in pain scale in both models.

Regarding genetic polymorphisms, in Model M the associated genotypes with lower pain sensitivity were rs6045819-A/G, rs10485703-C/T, rs910080-C/C, rs910079-C/C, and rs2235749-T/T, while for Model P the associated genotypes with lower pain sensitivity were rs6045819-A/G and rs35566036-del/del.

Table 6 A. ANOVA p-values obtained for two models of Generalised Estimating Equation. Model M uses the pain scale reported by the physician as a dependent variable, while Model P uses the pain scale reported by the patient. Significant p-values ($p < 0.01$) indicate the clinical variables and/or genetic variants that influence pain susceptibility.

Type of variable	Variables	Model M p-value	Model P p-value
Clinical variables	Time	~0	0.0001
	Age	0.0268	0.0336
	AP	0.0104	0.0155
	Ke8	0.0009	0.0234
	I	~0	~0
	rs6045819	0.009	0.009
	rs10485703	0.0058	0.0565
PDYN	rs910080	0.006	0.2713
	rs910079	0.0036	0.1247
	rs2235749	0.006	0.2713
	rs35566036	0.0436	0.0093
OPRK1	rs6985606	0.389	0.0698

p-values <0.01 were considered as significant values.

Table 6 B. Influence of clinical variables (Time, Ke8, I, AP and Age) on the pain scale reported by the physician or the patient. Coefficients, deviation standard and p-values of the generalised estimating equation (GEE). For each variable, the influence of the levels in the sensitivity to pain is shown. Negative coefficients for a level indicates lower pain respect to the reference level (coefficient for reference equals to zero).

Model M				Model P			
Levels	Coefficient	S.E.	p-value	Coefficient	S.E.	p-value	Influence
(Intercept)	7.412	0.897	~0	8.031	0.884	~0	
Time1	0	—	—	0	—	—	
Time2	-1.000	0.453	0.027	-1.000	0.592	0.091	-
Time12	-1.556	0.442	~0	-1.778	0.553	0.001	-
Time24	-2.259	0.401	~0	-2.519	0.520	~0	-
Age	-0.046	0.018	0.010	-0.041	0.023	0.070	-
AP (No)	0	—	—	0	—	—	
AP (Yes)	0.533	0.385	0.166	0.482	0.461	0.296	+
Ke8(No)	0	—	—	0.000	—	—	
Ke8(Yes)	-1.895	0.792	0.017	-1.934	0.817	0.018	-
I1	0	—	—	0	—	—	
I2	-1.350	0.485	0.005	-1.739	0.632	0.006	-
I3	-1.196	0.500	0.017	-1.868	0.553	0.001	-
I4	-1.071	0.698	0.125	-1.447	0.868	0.096	-
I5	-1.256	0.542	0.020	-1.783	0.598	0.003	-
rs6045819(A/G)	0	—	—	0	—	—	
rs6045819(A/A)	1.057	0.345	0.002	0.917	0.402	0.023	+
rs6045819(G/G)	1.087	0.660	0.100	2.086	0.733	0.004	+
rs10485703(C/T)	0	—	—	0.000	—	—	
rs10485703(T/T)	0.9816	0.356	0.006	0.893	0.468	0.057	+
rs910080(C/T)	0	—	—	0	—	—	
rs910080(C/C)	-0.8652	0.468	0.064	-0.190	0.595	0.750	-
rs910080(T/T)	0.4394	0.340	0.196	0.524	0.435	0.228	+
rs910079(C/T)	0	—	—	0	—	—	
rs910079(C/C)	-0.7167	0.485	0.139	0.079	0.576	0.891	-
rs910079(T/T)	0.5232	0.340	0.124	0.759	0.418	0.069	+
rs2235749(C/T)	0	—	—	0	—	—	
rs2235749(C/C)	0.4394	0.340	0.196	0.524	0.435	0.228	+
rs2235749(T/T)	-0.8652	0.468	0.064	-0.190	0.595	0.750	-
rs35566036(in/del)	0	—	—	0	—	—	
rs35566036(del/del)	-0.83785	0.346	0.016	-1.227	0.403	0.002	-
rs35566036(in/in)	-0.39242	0.369	0.287	-0.232	0.438	0.596	-
rs6985606(A/G)	0	—	—	0	—	—	
rs6985606(A/A)	0.2625	0.594	0.659	-1.031	0.612	0.092	+
rs6985606(G/G)	-0.4519	0.336	0.178	-0.575	0.408	0.159	-

Reference levels: Time1, Ke8(No), AP(No), and I1.

S.E. = standard error

DISCUSSION

The genetic basis influencing postoperative pain through the screening for variations in the expression of genes coding for endogenous opioid system is a field of interest for improving pain therapies (Stamer and Stüber, 2007; Montes *et al.*, 2015; Owusu Obeng *et al.*, 2017; Crews *et al.*, 2021).

In this work we analysed the genetic diversity of *PDYN* and *OPRK1* in Argentinian populations from different geographic locations, and the relationship between the genetic polymorphisms and the postsurgical pain,

considering variables such as the use of analgesia and the different types of incisions.

Our results show that the genetic background of the Argentinian population differs in some aspects from that of other countries and continents (Avena *et al.*, 2006; Hohl *et al.*, 2018). In a previous report, the variation of *OPRM1* gene of the opioid system allowed to group Argentinians with other populations according to their ancestry, with 12.8% of differentiation among Africans, Asians, and European-Americans for this gene (López Soto and Catanesi, 2015).

Genetic differences have also been found among different regions or provinces within Argentina, for several genetic polymorphisms, whether they were coding or non-coding markers (Corach *et al.*, 2006; Avena *et al.*, 2012; Di Santo Meztler *et al.*, 2018; Muzzio *et al.*, 2018; Sala *et al.*, 2018; Caputo *et al.*, 2021, among others). Interestingly, some differences emerged even when comparing Resistencia and MNP, which are located in the same province and only 425 km apart, as it was previously reported for non-coding markers (Di Santo Meztler *et al.*, 2019). Our results showed less genetic differentiation among Argentinian populations, probably because the polymorphisms here analyzed are located in coding regions, having less chances for displaying variability. However, a significant *F_{st}* value was found between populations from CABA and MNP for the *PDYN* VNTR. This differentiation could be caused by the heterogeneous origin of immigrants from other continents, mainly Europeans from various countries who have settled in the past in particular locations along the territory of Argentina, as in CABA (Junta de Estudios Históricos del Municipio de Eldorado, 2015, 2016; Di Santo Meztler *et al.*, 2018). As opposed, MNP is somehow isolated due to hard weather conditions and floods that discourage immigration.

Clinical variables

As several aspects of a surgical intervention can influence pain sensitivity, in this work we considered the interaction of both clinical variables and genetic variants.

When considering the evaluation of pain scale, the physician integrated the knowledge of the patient and the type of surgery performed, the questioning, the medical examination, and the data of the medical record (such as use of analgesics, calls to the nurse, rescue medication, etc.). Therefore, we considered that an evaluation by the professional (pain scale reported by the physician) is more trustworthy, and, in fact, significant associations of three clinical variables were found when analysing the medical pain scale.

Among the clinical variables to be taken into account, significant differences in reported pain scores were found according to the type of surgery. Although in the first two hours after the surgical intervention there were no differences between types of incision for pain scores, differences emerged as time increased, likely as a consequence of the severity of incision, being additionally influenced by biological factors as the genetic polymorphisms here analysed. Specifically, laparotomy incisions usually caused much higher pain scores on the first and second day after surgery than breast surgery incisions (either conservative or radical breast surgery). The results obtained in this work are in accordance with the grade of aggressivity of each

incision. Pfannenstiel laparotomy involves the handling of the aponeurosis, thus giving a high pain sensation at the beginning but recovering faster in comparison to Radian, and even faster in comparison to Arcuate, and Orr incisions, which are less aggressive and usually cause a lower level of pain sensation from the beginning. On the contrary, Median laparotomy is the more aggressive, and the level of pain sensation likely persists more constantly along the first two days after surgery.

Concerning the analgesic rescues, in general Klosidol was known to be well-tolerated as analgesia of choice for postsurgical pain in Latin American populations from Bolivia and Argentina, with a good balance cost/benefit when it was prescribed for relief of postsurgical pain treatment (Daza Calderón *et al.*, 2010). However, this combination of dextropropoxyphene and dipyrone was discontinued more recently because of some serious adverse effects that were reported for European populations (ANMAT, 2008). As expected, the analgesic rescues indicated in our study had a significant effect in decreasing the pain sensation during the first hours after surgery.

Genetic variables

Antinociception mediated by dynorphin and kappa receptors is known to be influenced by the sex of the patient, among other biological factors (Liu *et al.*, 2013). Moreover, the effect of certain *PDYN* polymorphisms has been reported showing sexual dimorphism, with a higher impact on females (Clarke *et al.*, 2012). Therefore, analysing genotype-phenotype association only in females avoids confounding results in this sense.

Among the genetic variants that we analysed, an association with pain sensitivity in the physician model was observed for one SNP (rs6045819) in the exon 4 and four SNPs (rs10485703, rs910080, rs910079, and rs2235749) in the 3'-UTR of *PDYN*. Genotypes associated with higher pain sensitivity were GG for rs6045819 and TT, TT, TT and CC respectively for 3'-UTR polymorphisms. There is evidence that exon 4 could be involved in *PDYN* splicing. This is supported by the significant association of the risk allele G (SNP rs6045819) with alcohol and/or cocaine dependence (Xuei *et al.*, 2006; Yuferov *et al.*, 2009). This risk allele could form a non-canonical E-box, which is a target of binding transcription factors that could modulate *PDYN* transcription, thus increasing the expression levels (Taqui, 2011). Regarding SNPs in the 3'-UTR of the gene, they are located close to each other, resulting in a significant LD among them (Supplementary Table 4). This genetic linkage is stronger among rs910080, rs910079 and rs2235749, likely transmitted in a block. This result is consistent with the finding that rs910079 can be chosen as a reporter of the block (Yuferov *et al.*, 2009). In addition, the haplotype rs910080-C /

rs910079-C / rs2235749-T has been proposed to be associated with a lower level of gene expression (Yuferov *et al.*, 2009).

Several works show that dynorphins inhibit nociceptive transmission in the spinal cord via interaction with the kappa opioid receptor (Werz and Macdonald, 1985; Randic *et al.*, 1995; Rusin *et al.*, 1997; Wiley *et al.*, 1997; Zachariou and Goldstein, 1997; Ogura and Kita, 2000). However, other authors have found evidence of dynorphin A having pronociceptive functions (Draisci *et al.*, 1991; Dubner and Ruda, 1992; Riley *et al.*, 1996; Vanderah *et al.*, 1996; Wagner and Deleo, 1996; Laughlin *et al.*, 1997; Malan *et al.*, 2000; Laughlin *et al.*, 2001). The switch between anti or pronociceptive effects of dynorphin A may depend on peptide concentrations, and kinetics of peptide interactions with either opioid or NMDA (N-methyl-D-aspartate) receptors. Dynorphins at physiological concentrations may be antinociceptive through the opioid receptors, typically playing an inhibitory role in acute pain conditions, whereas elevated pathophysiological levels may be pronociceptive and can interact with the NMDA receptors (Hauser *et al.*, 1999; Tan-No *et al.*, 2009). During peripheral inflammation, dynorphin induces its own synthesis through interaction with NMDA receptors, generating a regenerative, feed-forward process (Laughlin *et al.*, 2001).

In our work, we found genotypes that are associated with a high pain sensitivity and, according to bibliography, induce the expression of *PDYN*. We suggest that an overexpression of *PDYN* after surgery, in particular in patients with these genotypes, is giving rise to an activation of NMDA receptors, causing increased sensitivity to pain.

Concerning *OPRK1* gene, due to its wide presence in the central nervous system, its expression has been related to pain perception and behavioral traits as depression and drug abuse (Edenberg *et al.*, 2008; Bruchas *et al.*, 2010). The INDEL of *OPRK1*, rs35566036, was nearly significant for the model M. Different authors arrived to dissimilar conclusions on the importance of this polymorphism, either reporting a lack of association of this INDEL with the requirement of analgesia (Chatti *et al.*, 2017), or finding a regulatory effect on gene expression *in vitro* for the longer allele (insertion), thus acting as a transcriptional promoter with effect on a complex phenotype of alcohol dependence (Edenberg *et al.*, 2008). Our results are not conclusive for this matter, although the *p*-value near significance is suggestive of an influence of *OPRK1* INDEL on pain sensitivity. Increasing the sample number is probably needed in order to obtain a more accurate result.

Several previous reports on *PDYN* and *OPRK1* variation refer in general to dependence either on alcohol or drugs of abuse, given the abundance of dynorphin and kappa receptors on brain connections related to the formation of habits (Edenberg *et al.*, 2008; Zhang *et al.*, 2008; Dahl *et al.*, 2018; Hashemi *et al.*, 2018) and to emotional processing (Xu *et al.*, 2013). Other reports consider the influence of *PDYN* and *OPRK1* variants on pain modulation, mainly focused on chronic pain (Rosen *et al.*, 2000; Wang *et al.*, 2001; Podvin *et al.*, 2016; Tian *et al.*, 2018). Our results give an approach to the influence of the variation of both genes in pain, and suggest an association with levels of acute pain sensitivity and hyperalgesia after surgical intervention.

al., 2008; Dahl *et al.*, 2018; Hashemi *et al.*, 2018) and to emotional processing (Xu *et al.*, 2013). Other reports consider the influence of *PDYN* and *OPRK1* variants on pain modulation, mainly focused on chronic pain (Rosen *et al.*, 2000; Wang *et al.*, 2001; Podvin *et al.*, 2016; Tian *et al.*, 2018). Our results give an approach to the influence of the variation of both genes in pain, and suggest an association with levels of acute pain sensitivity and hyperalgesia after surgical intervention.

Concluding remarks

This is the first report on Argentinian population for *PDYN* variation, while information available on *OPRK1* variation and pain sensitivity in the same population is scarce (Raggio *et al.*, 2018), an unfavorable scene given the geographic extent and the heterogeneity of Argentinian people.

The results presented in this work show differences between Argentinians and populations from other continents, even in the comparison to Europeans, suggesting that a component of admixture with Native American people probably reinforce the differences. This, however, cannot be confirmed due to the scarce available information for Native Americans on variation of the genes of the endogenous opioid system (Ehlers *et al.*, 1998; Raggio *et al.*, 2018) and other genes related to pain perception (Catanesi and Glesmann, 2015; López-Cortés *et al.*, 2020). For this reason, an analysis on other populations of the region with known admixture with Native communities is needed. Although the number of individuals included in the analysis needs to be further increased, a genetic association with postsurgical acute pain phenotype has been found.

These findings highlight the importance of a regional study of genetic variants influencing pain sensitivity and analgesic response, in tune with the current tendency of a personal therapy medicine.

REFERENCES

- ANMAT - Administración nacional de medicamentos, alimentos y tecnología médica (2008) <https://www.argentina.gob.ar/anmat> (accessed January 27-2021).
- Avena S.A., Goicoechea A., Dugoujon J., Slepoy M., Slepoy A.S., Carnese F.R. (2001) Análisis antropogenético de los aportes indígena y africano en muestras hospitalarias de la ciudad de buenos aires. *Rev. Arg. de Antropología Biológica*. 3: 79-99.
- Avena S.A., Goicoechea A.S., Rey J., Dugoujon J.M., Dejean C., Carnese F.R. (2006) Mezcla génica en una muestra poblacional de la Ciudad de Buenos Aires. *Medicina (B Aires)* 66(2): 113-118.
- Avena S.A., Via M., Ziv E., Perez Stable J., Gignoux C., Dejean C., Huntsman S., Torres-Mejía G., Dutil J., Matta J.L., Beckman K., González Burchard E., Parolin M.L., Goicoechea A., Acreche N., Boquet M., Ríos Part M. d. C., Fernández V., Rey J., Stern M.C., Carnese R.F., Fejerman L. (2012) Heterogeneity in genetic admixture across different regions of argentina. *PLoS One* 7(4): e34695.

- Bruchas M., Land B., Chavkin C. (2010) The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. *Brain Res.* 1314: 44–55.
- Caputo M., Amador M.A., Sala A., Riveiro dos Santos A., Santos S., Corach D. (2021) Ancestral genetic legacy of the extant population of Argentina as predicted by autosomal and X-chromosomal DIPs. *Mol. Genet. Genomics* 296: 581–590.
- Carr D.B., Goudas L.C. (1999) Acute pain. *The Lancet* 353(9169): 2051–2058.
- Catanesi C.I., Glesmann L.A. (2015) Genetic drift among Native people from South American Gran Chaco region affects interleukin 1 receptor antagonist variation. In: Richardson J. (Ed.) *Natural Selection and Genetic Drift*. Nova Publishers, NY, pp.: 101–118.
- Cerrutti M. (2009) Diagnóstico de las poblaciones de inmigrantes en la argentina. Serie de documentos de la Dirección Nacional de Población. Ministerio del Interior de la República Argentina. http://www.mininterior.gov.ar/poblacion/pdf/Diagnostico_de_las_poblaciones_de_inmigrantes_en_Argentina.pdf (accessed October-12-2020).
- Chatti I., Woillard J.B., Mili A., Creveaux I., Ben Charfeddine I., Feki J., Langlais S., Fatma L.B., Saad A., Gribaa M., Libert F. (2017) Genetic analysis of mu and kappa opioid receptor and comt enzyme in cancer pain tunisian patients under opioid treatment. *Iran J. Public Health* 46(12): 1704–1711.
- Clarke T., Ambrose-Lanci L., Ferraro T., Berrettini W., Kampman K., Dackis C., Pettinati H., O'Brien C.P., Oslin D.W., Lohoff F.W. (2012) Genetic association analyses of pdyn polymorphisms with heroin and cocaine addiction. *Genes, Brain, Behav.* 11: 415–423.
- Corach D., Marino M., Sala A. (2006) Relevant genetic contribution of Amerindian to the extant population of Argentina. *International Congress Series: Progress in Forensic Genetics* 11. 1288: 397–399.
- Crews K.R., Monte A.A., Huddart R., Caudle K.E., Kharasch E.D., Gaedigk A., Dunnenberger H.M., Leeder J.S., Callaghan J.T., Samer C.F., Klein T.E., Haidar C.E., Van Driest S.L., Ruano G., Sangkuhl K., Cavallari L.H., Müller D.J., Prows C.A., Nagy M., Somogyi A.A., Skaar T.C. (2021) Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. *Clin. Pharmacol. Ther.* 110(4): 888–896.
- Dahl J.P., Weller A.E., Kampman K.M., Oslin D.W., Lohoff F.W., Ferraro R.N., O'Brien C.P., Berrettini W.H. (2018) Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 139(1): 106–108.
- Daza Calderón M., Rojas Ledesma R., Flores Miranda I., Choque Durán C., Alarcón Fernández N. (2010) Estudio de farmacovigilancia retrospectiva del klosidol inyectable en analgesia postoperatoria. *Rev. Inv. Inf. Salud* 5(12): 47–55.
- De Pompert de Valenzuela M.C. (2008) El poblamiento del chaco. Moglia SRL, Corrientes, Argentina.
- Di Santo Meztler G.P. (2018) Diversidad genética de la región no pseudoautosómica del cromosoma x en las poblaciones de corrientes y misiones: determinación de marcadores poblacionales y marcadores para identificación, Tesis Doctoral, Universidad de La Plata, Buenos Aires, Argentina.
- Di Santo Meztler G.P., del Palacio S., Esteban M.E., Armoa I., Argüelles C.F., Catanesi C.I. (2018) Genetic differentiation of northeast Argentina populations based on 30 binary x chromosome markers. *Front. Genet.* 9: Article 208.
- Di Santo Meztler G.P., Glesmann L.A., Esteban M.E., del Palacio S., Méndez M.G., Catanesi C.I. (2019) Comparative study of 10 x-str markers in populations of northeast Argentina. *Hum. Biol.* 91(1): 9–14.
- Draisci G., Kajander K.C., Dubner R., Bennett G.J., Iadarola M.J. (1991) Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. *Brain Res.* 560: 186–192.
- Dubner R., Ruda M.A. (1992) Activity-dependent neuronal plasticity following tissue injury and inflammation. *Trends. Neurosci.* 15: 96–103.
- Edenberg H., Wang J., Tian H., Pochareddy S., Xuei X., Wetherill L., Goate A., Hinrichs T., Kuperman S., Nurnberger Jr J.I., Schuckit M., Tischfield J.A., Foroud T. (2008) A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. *Hum. Mol. Genet.* 17: 1783–1789.
- Ehlers C.L., Garcia-Andrade C., Wall T.L., Sobel D.F., Phillips E. (1998) Determinants of p3 amplitude and response to alcohol in native american mission indians. *Neuropsychopharmacology* 18(4): 282–292.
- Excoffier, L. and H.E. L. Lischer (2010) Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. *Mol. Ecol. Resour.* 10: 564–567.
- Franceschi Z., (2010) El universo wichi: historia y cultura. En: Franceschi Z. y Dasso M. *Etno-grafías, la escritura como testimonio entre los wichi*. Corregidor, Buenos Aires, Argentina: 29–71.
- Gallo E., Cortés Conde R. (1967) La formación de la argentina moderna.: Paidós, Buenos Aires, Argentina.
- Gamboa Lerena M., del Palacio S., López Armengol F., Hohl D.M., Di Santo Meztler G. (2020) Ga-ta: Genetics application - table adapter. *BAG. J. Basic Appl. Genet.* 31(1): 71. En: *J. of Basic & Applied Genetics*, Vol. XXXI Suppl. 1: 9.
- Gemmell N.J., Akiyama S. (1996) An efficient method for the extraction of DNA from vertebrate tissues. *TIG* 12(9): 338–339.
- Halekoh U., Hojsgaard S., Yan J. (2006) The r package geepack for generalized estimating equations. *J. Stat. Softw.* 15: 1–11.
- Hashemi M., Shakiba M., Sanaei S., Shahkar G., Rezaei M., Mojahed A., Bahari G. (2018) Evaluation of prodynorphin gene polymorphisms and their association with heroin addiction in a sample of the southeast iranian population. *Mol. Biol. Res. Commun.* 7: 1–6.
- Hauser K.F., Foldes J.K., Turbek C.S. (1999) Dynorphin A (1–13) neurotoxicity in vitro: Opioid and non-opioid mechanisms in mouse spinal cord neurons. *Exp. Neurol.* 160: 361–375.
- Hohl D.M., Bezus B., Ratowiecki J., Catanesi C.I. (2018) Genetic and phenotypic variability of iris color in Buenos Aires population. *Genet. Mol. Biol.* 41(1): 50–58.
- Instituto Nacional de Asuntos Indígenas (INAI) (2005) Información estadística. En: Ministerio de Desarrollo Social, Presidencia de la Nación, República Argentina. <https://www.desarrollosocial.gob.ar/wp-content/uploads/2015/08/8.-INAI-Informacion-estadistica.pdf> (accessed 2020–November–23).
- Junta de Estudios Históricos del Municipio de Eldorado (2015). *Historias de Eldorado Vol. 2. Eldorado, Misiones. Argentina.*
- Junta de Estudios Históricos del Municipio de Eldorado (2016). *Historias de Eldorado Vol. 3. Eldorado, Misiones. Argentina.*
- Laughlin T.M., Vanderah T.W., Lashbrook J., Nichols M.L., Ossipov M., Porreca F., Wilcox G.L. (1997) Spinally administered dynorphin produces long-lasting allodynia: Involvement of nmda but not opioid receptors. *Pain* 72: 253–260.
- Laughlin T., Larson A., Wilcox G. (2001) Mechanisms of induction of persistent nociception by dynorphin. *J. Pharmacol. Exp. Ther.* 299(1): 6–11.
- Liu N., Schnell S., Wessendorf M., Gintzler A. (2013) Pain modality on dynorphin-mediated antinociception in rats. *J. Pharmacol. Exp. Ther.* 344: 522–530.
- López-Cortés A., Zambrano A.K., Guevara-Ramírez P., Echeverría B.A., Guerrero S., Cabascango E., Pérez-Villa A., Armendáriz-Castillo I., García-Cárdenas J.M., Yumiceba V., Pérez M.G., Leone P.E., Paz-Y-Miño C. (2020) Clinical, genomics and networking analyses of a high-altitude native American

- Ecuadorian patient with congenital insensitivity to pain with anhidrosis: a case report. *BMC Med Genomics* 13(1): 113.
- López Soto E., Catanesi C.I. (2015) Human population genetic structure detected by pain-related mu opioid receptor gene polymorphisms. *Genet. Mol. Biol.* 38: 152–155.
- Maeder E. (2012) *Historia del Chaco*. Editorial ConTexto, Chaco, Argentina.
- Malan T.P., Ossipov M.H., Gardell L.R., Ibrahim M., Bian D., Lai J., Porreca F. (2000) Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. *Pain* 86: 185–194.
- Montes A., Roca G., Sabate S., Lao J., Navarro A., Cantillo J., Canet J.; GENDOLCAT Study Group. (2015) Genetic and clinical factors associated with chronic postsurgical pain after hernia repair, hysterectomy, and thoracotomy a two-year multicenter cohort study. *Anesthesiology* 122(5): 1123–1141.
- Muzzio M., Motti J., Paz Sepúlveda P., Yee M., Cooke T., Santos M., Ramallo V., Alfaro E., Dipierri J., Bailliet G., Bravi C.M., Bustamante C.D., Kenny E.E. (2018) Population structure in Argentina. *PLoS One* 13(5): e0196325.
- Nikoshkov A., Drakenberg K., Wang X., Horvath M., Keller E., Hurd Y. (2008) Opioid neuropeptide genotypes in relation to heroin abuse: Dopamine tone contributes to reversed mesolimbic proenkephalin expression. *PNAS* 105(2): 786–791.
- Nosova O., Bazov I., Karpayak V., Hallberg M., Bakalkin G. (2021) Epigenetic and transcriptional control of the opioid prodynorphin gene: In-depth analysis in the human brain. *Molecules* 26: 3458.
- Ogura M., Kita H. (2000) Dynorphin exerts both postsynaptic and presynaptic effects in the globus pallidus of the rat. *J. Neurophysiol.* 83: 3366–3376.
- Owusu Obeng A., Hamadeh I., Smith M. (2017) Review of opioid pharmacogenetics and considerations for pain management. *Pharmacotherapy* 37(9): 1105–1121.
- Podvin S., Yaksh T., Hook V. (2016) Emerging role of spinal dynorphin in chronic pain, a therapeutic perspective. *Annu. Rev. Pharmacol. Toxicol.* 56: 511–533.
- R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>. (accessed June 1 2022).
- Raggio M.C., González R., Hohl D.M., Glesmann L.A., Catanesi C.I. (2018) Genetic variations of OPRM1, OPRK1, and COMT genes and their possible associations with oral pain in a population from Argentina. *J. Oral & Facial Pain and Headache* 32: 367–374.
- Randic M., Cheng G., Kojic L. (1995) Kappa-opioid receptor agonists modulate excitatory transmission in substantia gelatinosa neurons of the rat spinal cord. *J. Neurosci.* 15: 6809–6826.
- Riley R.C., Zhao Z.Q., Duggan A.W. (1996) Spinal release of immunoreactive dynorphin A (1–8) with the development of peripheral inflammation in the rat. *Brain Res.* 710: 131–142.
- Rosen A., Lundeberg T., Bytner B., Nylander I. (2000) Central changes in nociceptin dynorphin b and met-enkephalin-arg-phe in different models of nociception. *Brain Res.* 857: 212–218.
- Rusin K.I., Giovannucci D.R., Stuenkel E.L., Moises H.C. (1997) Kappa-opioid receptor activation modulates Ca²⁺ currents and secretion in isolated neuroendocrine nerve terminals. *J. Neurosci.* 17: 6565–6574.
- Sala A., Caputo M., Ginart S., Theiler G., Parolin M.L., Carnese R.F., Fainboim L., Corach D. (2018) Historical records under the genetic evidence: Chiriguano tribe genesis as a test case. *Mol. Biol. Reports* 45: 987–987.
- Schreiber K., Kehlet H., Belfer I., Edwards R. (2014) Predicting, preventing and managing persistent pain after breast cancer surgery: the importance of psychosocial factors. *Pain Manag.* 4(6): 445–459.
- Schwarzer C. (2009) 30 years of dynorphins—new insights on their functions in neuropsychiatric diseases. *Pharmacol. Ther.* 123: 353–370.
- Sevini F., Yao D., Lomartire L. (2013) Analysis of population substructure in two sympatric populations of Gran Chaco, Argentina. *PLoS One* 8: e64054.
- Solé X., Guino E., Valls J., Iñiesta R., Moreno V. (2006) SNPStats: a web tool for the analysis of association studies. *Bioinformatics* 22: 1928–1929.
- Stamer U., Stüber F. (2007) The pharmacogenetics of analgesia. *Expert Opin. Pharmacother.* 8: 2235–2245.
- Tan-No K., Takahashi H., Nakagawasai O., Nijima F., Sakurada S., Bakalkin G., Terenius L., Tadano T. (2009) Nociceptive behavior induced by the endogenous opioid peptides dynorphins in uninjured mice: evidence with intrathecal n-ethylmaleimide inhibiting dynorphin degradation. *Int. Rev. Neurobiol.* 85: 191–205.
- Taqi M.M. (2011) Mechanisms of prodynorphin gene dysregulation in the brain of human alcoholics. Ph.D. thesis, Sweden: University of Uppsala, Sweden.
- Tian Y., Liu X., Jia M., Yu H., Lichtner P., Shi Y., Meng Z., Kou S., Ho I., Jia B., Cheng B.C.P., Lam C.K.M., Tsang S., Wong S.H., Yu J., Cheng C.H.K., Wu W.K.K., Chen Z., Chan M.T.V. (2018) Targeted genotyping identifies susceptibility locus in brain-derived neurotrophic factor gene for chronic postsurgical pain. *Anesthesiology* 128(3): 587–597.
- Tissera R. (2008) Chaco, historia general. Subsecretaría de Cultura, Min. de Educación, Cultura, Ciencia y Tecnología de la provincia de Chaco. Librería de la Paz, Resistencia, Chaco, Argentina.
- Torrado S. (1992) Estructura social de la Argentina: 1945–1983. Ediciones de la Flor, Buenos Aires, Argentina.
- Vanderah T.W., Laughlin T., Lashbrook J.M., Nichols M.L., Wilcox G.L., Ossipov M.H., Malan T.P., Porreca F. (1996) Single intrathecal injections of dynorphin a or des-tyr-dynorphins produce long-lasting allodynia in rats: Blockade by mk-801 but not naloxone. *Pain* 68: 275–281.
- Wagner R., Deleo J.A. (1996) Pre-emptive dynorphin and n-methyl-d-aspartate glutamate receptor antagonism alters spinal immunocytochemistry but not allodynia following complete peripheral nerve injury. *Neuroscience* 72: 527–534.
- Wang Z., Gardell L., Ossipov M., Vanderah T., Brennan M. (2001) Pronociceptive actions of dynorphin maintain chronic neuropathic pain. *J. Neurosci.* 21: 1779–86.
- Werz M.A., Macdonald R.L. (1985) Dynorphin and neodynorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration. *J. Pharmacol. Exp. Ther.* 234: 49–56.
- Wiley J.W., Moises H.C., Gross R.A., MacDonald R.L. (1997) Dynorphin a-mediated reduction in multiple calcium currents involves a g (o) alpha-subtype g protein in rat primary afferent neurons. *J. Neurophysiol.* 77: 1338–1348.
- Xu K., Seo D., Hodgkinson C., Hu Y., Goldman D., Sinha R. (2013) A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk. *Translational Psychiatry* 3: e292.
- Xuei X., Dick D., Flury-Wetherill L., Tian H., Agrawal A., Bierut L., Goate A., Bucholz K., Schuckit M., Nurnberger J. (2006) Association of the kappa-opioid system with alcohol dependence. *Mol Psychiatry* 11: 1016–1024.
- Yuferov V., Ji F., Nielsen D., Levran O., Ho A., Morgello S., Shi R., Ott J., Kreek M. (2009) A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced pdyn expression in human brain. *Neuropsychopharmacology* 34(5): 1185–1197.
- Zachariou V., Goldstein B.D. (1997) Dynorphin-(1–8) inhibits the release of substance p-like immunoreactivity in the spinal cord of rats following a noxious

mechanical stimulus. *Eur. J. Pharmacol.* 323: 159–165.

Zhang H., Kranzler H., Yang B.Z., Luo X., Gelernter J. (2008) The *opr1* and *opr1* loci in alcohol or drug dependence: *Opr1* variation modulates substance dependence risk. *Mol. Psychiatry* 13(5): 531–543.

Zimprich A., Kraus J., Wöltje M., Mayer P., Rauch E., Höllt V. (2000) An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. *J. Neurochem.* 74: 472–477.

ACKNOWLEDGEMENTS

This research was supported by grants from Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, Argentina, PIP 2015–2017/0930), Agencia Nacional de Promoción Científica y Tecnológica (PICT –2020–SERIEA–01075), and from Universidad Nacional de La Plata (UNLP, Argentina, PID 2019–2020/N895). We would like to acknowledge Dr. Laura Angela Glesmann, MSc. Raúl Jorge Bridi and Dr. María Celeste Raggio for being part of the field trips for sample collection. We also thank Mr. Eduardo César Bauzá for the English language revision, and two anonymous reviewers of the manuscript.

—